Quick Answer
NORTHWEST BIOTHERAPEUTICS INC reported Total Revenue of $1.38 million for fiscal year 2024.
NORTHWEST BIOTHERAPEUTICS INC — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Total Revenue | $1.38M -28.5% |
$1.93M +14.8% |
$1.68M +67.5% |
$1.00M -22.2% |
$1.29M -46.4% |
$2.41M +485.0% |
| Revenue (ASC 606) | $1.38M -28.5% |
$1.93M | — | — | — | — |
| Net Income | -$83.78M -33.8% |
-$62.60M +40.4% |
-$105.03M -158.6% |
$179.13M +133.8% |
-$529.82M -2445.7% |
-$20.81M +41.9% |
| Diluted EPS | -$0.07 -16.7% |
-$0.06 +40.0% |
-$0.10 -66.7% |
-$0.06 +91.8% |
-$0.73 -1725.0% |
-$0.04 |
| Total Assets | $26.73M -4.1% |
$27.86M -11.0% |
$31.32M -22.0% |
$40.16M +22.1% |
$32.90M +209.1% |
$10.64M -56.9% |
| Cash and Equivalents | $2.17M +2.3% |
$2.13M -69.5% |
$6.96M -54.1% |
$15.17M +51.9% |
$9.98M +2583.6% |
$372.0K -98.3% |
| Stockholders Equity | -$94.49M -43.7% |
-$65.77M +48.7% |
-$128.10M -3.3% |
-$123.99M +65.8% |
-$362.95M -705.6% |
-$45.05M +6.4% |
| R&D Expense | $34.89M +25.8% |
$27.73M -21.9% |
$35.51M +74.9% |
$20.31M -39.6% |
$33.64M +138.5% |
$14.11M -22.3% |
| Operating Income | -$66.51M -19.8% |
-$55.51M +17.4% |
-$67.18M -27.5% |
-$52.70M +39.1% |
-$86.61M -209.5% |
-$27.98M +32.5% |
| Shares Outstanding | 1.33B +13.0% |
1.18B +10.0% |
1.07B +12.7% |
948.40M +14.3% |
829.60M +35.0% |
614.30M +17.4% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $200.0K | -44.0% | +52.7% |
| Revenue (ASC 606) | September 30, 2025 | $200.0K | -44.0% | +52.7% |
| Net Income | September 30, 2025 | -$26.83M | -38.5% | -74.5% |
| Diluted EPS | September 30, 2025 | -$0.02 | +0.0% | -100.0% |
| Total Assets | September 30, 2025 | $30.61M | +4.4% | +3.6% |
| Cash and Equivalents | September 30, 2025 | $4.56M | +55.2% | +5.7% |
| Stockholders Equity | September 30, 2025 | -$108.65M | -35.6% | -8.2% |
| R&D Expense | September 30, 2025 | $7.45M | -8.4% | +0.3% |
| Operating Income | September 30, 2025 | -$14.32M | +3.2% | +3.1% |
| Shares Outstanding | September 30, 2025 | 1.52B | +18.0% | +4.1% |
- NORTHWEST BIOTHERAPEUTICS INC reported Total Revenue of $1.38 million for fiscal year 2024.
- NORTHWEST BIOTHERAPEUTICS INC showed a decrease of -28.5% in Total Revenue compared to the prior fiscal year.
- NORTHWEST BIOTHERAPEUTICS INC reported Revenue (ASC 606) of $1.38 million for fiscal year 2024.
- NORTHWEST BIOTHERAPEUTICS INC showed a decrease of -28.5% in Revenue (ASC 606) compared to the prior fiscal year.
- NORTHWEST BIOTHERAPEUTICS INC reported Net Income of -$83.78 million for fiscal year 2024.
- NORTHWEST BIOTHERAPEUTICS INC showed a decrease of -33.8% in Net Income compared to the prior fiscal year.
- NORTHWEST BIOTHERAPEUTICS INC reported Diluted EPS of $0.07 per share (loss) for fiscal year 2024.
- NORTHWEST BIOTHERAPEUTICS INC showed a decrease of -16.7% in Diluted EPS compared to the prior fiscal year.
- NORTHWEST BIOTHERAPEUTICS INC reported Total Assets of $26.73 million for fiscal year 2024.
- NORTHWEST BIOTHERAPEUTICS INC showed a decrease of -4.1% in Total Assets compared to the prior fiscal year.
- NORTHWEST BIOTHERAPEUTICS INC reported Cash and Equivalents of $2.17 million for fiscal year 2024.
- NORTHWEST BIOTHERAPEUTICS INC showed an increase of +2.3% in Cash and Equivalents compared to the prior fiscal year.
- NORTHWEST BIOTHERAPEUTICS INC reported Stockholders Equity of -$94.49 million for fiscal year 2024.
- NORTHWEST BIOTHERAPEUTICS INC showed a decrease of -43.7% in Stockholders Equity compared to the prior fiscal year.
- NORTHWEST BIOTHERAPEUTICS INC reported R&D Expense of $34.89 million for fiscal year 2024.
- NORTHWEST BIOTHERAPEUTICS INC showed an increase of +25.8% in R&D Expense compared to the prior fiscal year.
- NORTHWEST BIOTHERAPEUTICS INC reported Operating Income of -$66.51 million for fiscal year 2024.
- NORTHWEST BIOTHERAPEUTICS INC showed a decrease of -19.8% in Operating Income compared to the prior fiscal year.
- NORTHWEST BIOTHERAPEUTICS INC reported Shares Outstanding of 1.33 billion shares for fiscal year 2024.
- NORTHWEST BIOTHERAPEUTICS INC showed an increase of +13.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: